Trial Profile
An Open Label, Safety Study to Assess the Potential for Adrenal Suppression and Pharmacokinetics Following Maximal Use Treatment With Topicort (Desoximetasone) Topical Spray, 0.25% in Pediatric Patients With Plaque Psoriasis.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Mar 2023
Price :
$35
*
At a glance
- Drugs Desoximetasone (Primary)
- Indications Plaque psoriasis
- Focus Pharmacodynamics
- Sponsors Taro Pharmaceuticals USA
- 21 Apr 2020 Status changed from recruiting to completed.
- 08 Apr 2019 Planned primary completion date changed from 1 Nov 2018 to 1 Nov 2019.
- 26 Jan 2018 Planned End Date changed from 1 Apr 2019 to 1 Dec 2018.